Table 4.
More frequent adverse events from the retrospective integrated safety analysis of data from 1,035 SOF/VEL for 12 Weeks patients and control/placebo patients in ASTRAL-1, -2, and -3
| Patients, n (%) | SOF/VEL 12 weeks N=1035 | Placebo 12 weeks N=116 |
| Headache | 296 (29) | 33 (28) |
| Fatigue | 217 (21) | 23 (20) |
| Nausea | 135 (13) | 13 (11) |
| Insomnia | 87 (8) | 11 (9) |
| Nasopharyngitis | 121 (12) | 12 (10) |
| Cough | 57 (6) | 4 (3) |
| Irritability | 49 (5) | 4 (3) |
| Pruritus | 33 (3) | 5 (4) |
| Dyspepsia | 33 (2) | 4 (3) |